Show simple item record

dc.contributor.authorIvanov, Andrei
dc.contributor.authorSwann, Ruth
dc.contributor.authorIllidge, Timothy M
dc.date.accessioned2009-05-12T16:19:39Z
dc.date.available2009-05-12T16:19:39Z
dc.date.issued2008-08
dc.identifier.citationNew insights into the mechanisms of action of radioimmunotherapy in lymphoma. 2008, 60 (8):987-98 J. Pharm. Pharmacol.en
dc.identifier.issn0022-3573
dc.identifier.pmid18644192
dc.identifier.doi10.1211/jpp.60.8.0006
dc.identifier.urihttp://hdl.handle.net/10541/67948
dc.description.abstractThe exquisite sensitivity of haematological malignancies to targeted radiation alongside the impressive results achieved by the pioneers in this field suggests that radioimmunotherapy is likely to be a productive area for future clinical research. Recent experimental work has demonstrated that the combination of targeted radiation and antibody effector mechanisms are critical to long-term clearance of tumour. This review provides the background of clinical and biological insights into the mechanisms of action of radioimmunotherapy.
dc.language.isoenen
dc.subject.meshAlgorithms
dc.subject.meshAnimals
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshDecision Trees
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshHumans
dc.subject.meshLymphoma
dc.subject.meshRadioimmunotherapy
dc.subject.meshRadiopharmaceuticals
dc.subject.meshRadiotherapy Dosage
dc.subject.meshTreatment Outcome
dc.titleNew insights into the mechanisms of action of radioimmunotherapy in lymphoma.en
dc.typeArticleen
dc.contributor.departmentSchool of Cancer and Imaging Sciences, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.en
dc.identifier.journalThe Journal of Pharmacy and Pharmacologyen
html.description.abstractThe exquisite sensitivity of haematological malignancies to targeted radiation alongside the impressive results achieved by the pioneers in this field suggests that radioimmunotherapy is likely to be a productive area for future clinical research. Recent experimental work has demonstrated that the combination of targeted radiation and antibody effector mechanisms are critical to long-term clearance of tumour. This review provides the background of clinical and biological insights into the mechanisms of action of radioimmunotherapy.


This item appears in the following Collection(s)

Show simple item record